Authors
Liming Zhang, Meilin Chen, Zhen Yang, Meiling Gong, Ruilian Yu
Published in
Journal of gynecologic oncology. Sep 11, 2026. Epub Sep 11, 2026.
Abstract
To evaluate the association between bevacizumab relative dose intensity (RDI) and first-line treatment outcomes in advanced epithelial ovarian cancer.
We retrospectively analyzed 72 patients treated with first-line bevacizumab plus paclitaxel-platinum chemotherapy between January 2019 and September 2024. Patients were categorized using X-tile-derived RDI cutoffs as low (≤0.61), intermediate (>0.61 to <0.93), or high (≥0.93). Objective response rate (ORR), progression-free survival (PFS), and adverse events were compared, and Cox proportional hazards regression was used to assess factors associated with PFS.
ORRs were 40.0%, 75.0%, and 80.0% in the low-, intermediate-, and high-RDI groups, respectively (p=0.011). Median PFS was 12.6, 21.2, and 23.5 months, respectively (log-rank p=0.037), with the greatest difference between the low- and high-RDI groups (p=0.018). In multivariable analysis, high versus low RDI was associated with a lower risk of progression (hazard ratio=0.463; 95% confidence interval=0.235-0.913; p=0.026). Overall adverse-event incidence did not differ significantly among groups; however, grade 3-4 neutropenia and thromboembolic events were significantly more frequent in the high- than low-RDI group.
Lower bevacizumab RDI was associated with poorer response and shorter PFS. Given the retrospective single-center design, the optimal RDI threshold requires validation in larger prospective studies.
PMID:
42750305
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0